Celltrion’s Herzuma (Trastuzumab Biosimilar, CT-P6) Receives EMA Approval for Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer

 Celltrion’s Herzuma (Trastuzumab Biosimilar, CT-P6) Receives EMA Approval for Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer

Celltrion’s Herzuma (Trastuzumab Biosimilar, CT-P6) Receives EMA Approval for Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer

Shots:

  • The approval is based on positive opinion by CHMP (EMA) assessing Herzuma and reference trastuzumab in patients with HER2 overexpression/gene amplification tumors in breast cancer, metastatic breast cancer and metastatic gastric cancer
  • The study resulted in a non-inferiority data demonstrating efficacy, safety, immunogenicity, PD and PK in patients
  • Herzuma (trastuzumab biosimilar, CT-P6) is a mAb, that binds to extracellular domain of human epidermal growth factor receptor (HER2) and is currently reviewed by FDA review in the USS

Click here read full press release/ article | Ref: Celltrion | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post